GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-02-23| Partnerships

Moderna, Life Edit To Develop In Vivo Gene Editing Therapies

by Joy Lin
Share To

Moderna has tapped Life Edit Therapeutics, an ElevateBio company, to discover and develop in vivo mRNA gene editing therapies. 

The multi-target partnership will combine Life Edit’s gene editing technologies, including base editing, with Moderna’s mRNA platform to develop in vivo mRNA gene editing therapies against an undisclosed set of targets. 

“This collaboration between Life Edit and Moderna demonstrates the strength of our respective technologies to advance programmable medicines to more specifically target disease,” said Mitchell Finer, Ph.D., CEO of Life Edit Therapeutics and President of R&D at ElevateBio. 

“Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development. We are excited that partners, such as Moderna, are recognizing the potential of our technology.”

Moderna began the year with its first-ever acquisition of Japanese DNA manufacturer OriCiro Genomics for $85 million. The purchase adds cell-free DNA synthesis and plasmid DNA amplification to Moderna’s repertoire, which could potentially accelerate its R&D engine. 

Related article: Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease 

Base Editors and RNA-guided Nucleases

Life Edit’s gene editing platform offers a library of base editors and RNA-guided nucleases (RGNs). RGNs are smaller than conventional nucleases, which may enable greater versatility for delivery. 

The company’s nuclease collection includes a range of Protospacer Adjacent Motifs (PAMs), short sequences that determine the DNA segments in the genome to which a nuclease can bind. According to Life Edit, the diversity of their PAMs enables base editing at more sites than any nuclease can achieve, which could offer unprecedented access to the genome to target diseases.  

Under the collaboration, Moderna will fund research and preclinical studies by Life Edit. Upon opting in on a target, Moderna will take over further development, production, and commercialization. Life Edit will receive an undisclosed upfront sum and could receive potential milestone payments as well as tiered royalties for each target chosen by Moderna. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
2025-01-22
Moderna and Mitsubishi Tanabe Pharma Partner on mRNA Respiratory Vaccines in Japan
2024-07-11
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top